(Q39414225)

11 September 2017

title

Effect of rizatriptan and other triptans on the nausea symptom of migraine: a post hoc analysis (English)

1 reference

11 September 2017

1 reference

1

R B Lipton

1 reference

11 September 2017

3

P J Goadsby

1 reference

11 September 2017

J Pascual

2

1 reference

11 September 2017

H Massiou

4

1 reference

11 September 2017

K A McCarroll

5

1 reference

11 September 2017

K Vandormael

6

1 reference

11 September 2017

K Jiang

7

1 reference

11 September 2017

C R Lines

8

1 reference

11 September 2017

publication date

1 September 2001

1 reference

11 September 2017

1 reference

11 September 2017

volume

41

1 reference

11 September 2017

issue

8

1 reference

11 September 2017

page(s)

754-763

1 reference

Naratriptan is effective and well tolerated in the acute treatment of migraine. Results of a double-blind, placebo-controlled, crossover study. The Naratriptan S2WA3003 Study Group

11 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1526-4610.2001.01139.X

Eletriptan in acute migraine: a double-blind, placebo-controlled comparison to sumatriptan. Eletriptan Steering Committee.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1526-4610.2001.01139.X

Oral rizatriptan versus oral sumatriptan: a direct comparative study in the acute treatment of migraine. Rizatriptan 030 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1526-4610.2001.01139.X

Crossover comparison of rizatriptan 5 mg and 10 mg versus sumatriptan 25 mg and 50 mg in migraine. Rizatriptan Protocol 046 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1526-4610.2001.01139.X

Comparison of rizatriptan 10 mg vs. naratriptan 2.5 mg in migraine

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1526-4610.2001.01139.X

Comparison of rizatriptan 10 mg vs. zolmitriptan 2.5 mg in the acute treatment of migraine. Rizatriptan-Zolmitriptan Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1526-4610.2001.01139.X

Rizatriptan vs sumatriptan in the acute treatment of migraine. A placebo-controlled, dose-ranging study. Dutch/US Rizatriptan Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1526-4610.2001.01139.X

Pathophysiology and pharmacology of migraine. Is there a place for antiemetics in future treatment strategies?

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1526-4610.2001.01139.X

Inhibition by sumatriptan of central trigeminal neurones only after blood-brain barrier disruption

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1526-4610.2001.01139.X

A phase II multicenter dose-finding, efficacy and safety trial of ipsapirone in outpatients with generalized anxiety disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1526-4610.2001.01139.X

Clinical efficacy and tolerability of 2.5 mg zolmitriptan for the acute treatment of migraine. The 042 Clinical Trial Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1526-4610.2001.01139.X

10.1046/J.1526-4610.2001.01139.X

21 January 2018

Identifiers

DOI

1 reference

11 September 2017

1 reference